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Background: Inhibition of TNFα protects the retina against diabetic-like changes in rodent models. The mechanism
by which TNFα induces deleterious retinal changes is not known. Previously, we have shown that TNFα can inhibit
normal insulin signal transduction, leading to increased apoptosis in both retinal endothelial cells (REC) and Müller
cells. Additionally, β2-adrenergic receptor knockout mice (β2KO) have increased TNFα levels and decreased insulin
receptor activity. In this study, we hypothesized that inhibition of TNFα in β2KO mice would increase normal insulin
signaling, leading to improved retinal function.
Methods: C57BL6 or β2KO mice were left untreated or treated with etanercept (0.3 mg/kg subcutaneously, 3× a week)
for 2 months. Electroretinogram analyses were done before treatment was initiated and after two months of treatment
with etanercept on all mice. Western blot or ELISA analyses were done on whole retinal lysates from all four groups of
mice for TNFα, suppressor of cytokine signaling 3 (SOCS3), insulin receptor, and apoptotic proteins.
Results: Etanercept significantly reduced TNFα levels in β2KO mice, leading to increased insulin receptor
phosphorylation on tyrosine 1150/1151. SOCS3 levels were increased in β2KO mice, which were reduced after
etanercept treatment. Pro-apoptotic proteins were reduced in etanercept-treated β2KO mice. Etanercept improved ERG
amplitudes in β2KO mice.
Conclusions: Inhibition of TNFα by etanercept protects the retina likely through reduced TNFα-mediated insulin
resistance, leading to reduced apoptosis.
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The role of sympathetic nerves in diabetes has not been
questioned when focusing on peripheral nerve disease
[1]. Work has demonstrated that diabetes and aging can
both produce significant remodeling of sympathetic gan-
glia and neurotransmission [2]. However, the role of sym-
pathetic nerve activity in the retina is less clear. Work by
our group demonstrated that loss of dopamine beta hy-
droxylase (a key enzyme required for the production of
norepinephrine) produces substantial changes to the ret-
ina [3]. Subsequently, we have shown that β-adrenergic* Correspondence: jsteinl1@uthsc.edu
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unless otherwise stated.receptors are key to retinal damage, which is similar to
retinal changes observed in animal models of diabetic
retinopathy [4,5]. Recently, we showed that treatment
of β2KO mice with a novel β1/β2-adrenergic receptor
agonist, Compound 49b, could prevent impaired insulin
receptor signal transduction [6] observed in both dia-
betic rodent models [7], as well as retinal endothelial
[8] and Müller cells [9] grown under hyperglycemia
conditions. Retinal endothelial cells express only β1-
and β3-adrenergic receptors [10], while retinal Müller
cells express both β1- and β2-adrenergic receptors [11].
Therefore, use of the β2-adrenergic receptor knockout
mice (β2KO) mice could suggest that the retinal
changes observed in these mice are produced by retinal
endothelial cells through activation of β1- and/or β3-
adrenergic receptor signaling. Since we have shown thattd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sponse to high glucose and impaired insulin signaling,
it is likely that impaired insulin signaling may be key to
apoptosis in the retina [8].
In our previous work in retinal endothelial cells, we
have reported that high glucose increases TNFα levels,
leading to apoptosis of these cells [8]. Others have also
reported that increased cytokine levels can lead to apop-
tosis of retinal endothelial cells [12]. Increased TNFα
can produce insulin resistance in multiple ways. The
most direct pathway of TNFα-induced inhibition of in-
sulin signaling is through TNFα-mediated phosphoryl-
ation of insulin receptor substrate 1 (IRS-1) on serine
307 [13]. Phosphorylation of serine 307 on IRS-1 inhibits
the ability of IRS-1 to transmit the insulin phosphoryl-
ation signal to Akt, thus blocking normal insulin signal
transduction. In addition to actions on IRS-1, TNFα also
leads to increased suppressor of cytokine signaling 3
(SOCS3) levels [14,15]. Increased SOCS3 levels can phos-
phorylate the insulin receptor on tyrosine 960 which
blocks the insulin receptor/IRS-1 interaction [16]. We
have previously reported that TNFα and SOCS3 are both
increased in response to high glucose in retinal endothelial
cells, leading to increased phosphorylation of IRS-1Ser307
and IRTyr960 [8]. The remaining question was whether this
occurred in vivo and whether inhibition of TNFα could
block all downstream responses to restore normal insulin
signal transduction.
The suggestion of inhibition of TNFα as a therapeutic
for diabetic retinopathy is not novel. Because TNFα is
reported to cause insulin resistance in many other tis-
sues, including adipocytes [13] and myeloid progenitor
cells [17], it would be expected that inhibition of TNFα
would protect cells and normalize insulin signaling. This
was directly tested in chronic studies in TNFα receptor
1- or receptor 2-deficient mice fed 30% galactose for up
to 20 months. The authors found that inhibition of
TNFα with etanercept (Enbrel), a TNFα receptor antag-
onist, in galactosemic rats led to reduced pericyte loss
and degenerate capillary formation [18]. Additionally, in
acute studies of retinopathy-like changes, the authors
demonstrated that etanercept suppressed caspase activity
and apoptosis in Long Evans rats treated with streptozo-
tocin to make them diabetic [18]. Previously, this group
had reported that etanercept reduced leukocyte adhesion
in diabetic rats [19]. Therefore, it is clear that inhibition
of TNFα is protective against diabetic retinopathy changes;
however, the mechanism by which this may occur is
unknown.
Our hypothesis was that inhibition of TNFα actions in
β2KO mice would restore normal insulin signal transduc-
tion, explaining the improvement in markers of diabetic
retinopathy reported by others. To test our hypothesis, we
treated wildtype mice or β2KO mice with etanercept fortwo months and measured proteins involved in insulin re-
sistance and signaling, including TNFα, SOCS3, insulin
receptor (IR), and apoptotic markers. We found that in-
hibition of TNFα by etanercept treatment to β2KO mice
was able to significantly reduce apoptotic markers through
decreased activation of TNFα-mediated insulin resistance.
Methods
Mice
All mice experiments, including those for dark-adaptation
and tail electrodes for electroretinogram (ERG) analyses,
were approved by the Institutional Animal Care and Use
Committee at the University of Tennessee Health Science
Center (Protocol #1992). β1/β2KO mice (Adrb1tm1Bkk
Adrb2tm1Bkk/J) were purchased from Jackson Laboratories
(Bar Harbor, ME, USA). From the β1/β2KO mice, we bred
mice to generate only homozygous β2KO mice. We ap-
preciate that C57BL6 may not be the ideal wildtype con-
trol, but the original β1/β2KO mice were from a mixed
background containing C57BL6, therefore we chose the
C57BL6 for wildtype. Since we use these mice at three
months of age, other issues from the C57BL6 background
should be minimized. We have previously published use
of this animal model and genotyping [5] to demonstrate
that neuronal markers of diabetic retinopathy are present,
as well as increased apoptosis in the retina.
Etanercept (Enbrel) treatment
A subset of the β2KO mice were administered Enbrel by
subcutaneous injection 0.3 mg/kg, 3×/week) [19]. After
the final treatment, C57BL6 control, C57BL6+ etaner-
cept, β2KO mice, and β2KO mice + etanercept (five mice
of each gender in each group) were dark-adapted for
ERG analyses prior to sacrifice by ketamine and xylazine
overdose.
Electroretinogram
Prior to sacrifice for morphological and biochemical ana-
lyses, animals were subjected to ERG analyses to evaluate
the changes in the electrical activity of the retina as we
have done previously [5,7]. After dark-adaptation over-
night, ERG responses were recorded from both eyes to-
gether using platinum wire corneal electrodes, forehead
reference electrode, and ground electrode in the tail.
Pupils were fully dilated using 1% tropicamide solution
(Alcon, Ft. Worth, TX, USA). Methylcellulose (Cellu-
vise; Allergan, Irvine, CA, USA) drops were applied as
well to maintain a good electrical connection and body
temperature was maintained at 37°C by a water-based
heating pad. ERG waveforms were recorded with
a bandwidth of 0.3 to 500Hz and sampled at 2 kHz by a
digital acquisition system and were analyzed using
a custom-built program (MatLab, Mathworks, Natick,
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plitudes of the A- and B-wave of each treatment group.
Western blot analysis
Equal amounts of protein from the tissue extracts were
separated on the pre-cast tris-glycine gel (Invitrogen,
Carlsbad, CA, USA), blotted onto a nitrocellulose mem-
brane. After blocking in TBST (10 mM Tris–HCl buffer,
pH 8.0, 150 mM NaCl, 0.1% Tween 20) and 5% (w/v)
BSA, the membrane was treated with appropriate pri-
mary antibodies followed by incubation with secondary
antibodies labeled with horseradish peroxidase. Antigen-
antibody complexes were detected by a chemilumines-
cence reagent kit (Thermo Scientific, Waltham, MA,
USA). Primary antibodies used were phosphorylated Akt
(Serine 473), Akt, Bax, Bcl-xL, Cytochrome C, SOCS3,
phosphorylated insulin receptor (tyrosine 1150/1151), in-
sulin receptor (all purchased from Cell Signaling, Danvers,
MA, USA), insulin receptor phosphorylated on Tyr960
(Cell Applications, San Diego, CA, USA), and beta actin
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).
ELISA analysis
A cleaved caspase 3 ELISA (Cell Signaling, Danvers,
MA, USA) was used to measure levels of the active
apoptotic marker in whole retinal lysates. TNFα protein
concentrations were measured using a TNFα ELISA
(ThermoFisher, Pittsburgh, PA, USA). For cleaved cas-
pase 3 ELISA analyses, equal protein was loaded (50 μg)
into all wells to allow for comparisons based on optical
density (OD). For the TNFα ELISA, 50 μl protein was
loaded into all wells, with analyses for concentrations
based on a standard curve.Figure 1 Enbrel reduced TNFα and IRS-1Ser307 phosphorylation, while
shows results for wildtype (WT) and β2KO (β2KO) mice only or WT and β2K
was effective in reducing TNFα levels, which are increased in β2KO only m
1150/1151 are reduced in β2KO mice, which are restored after etanercept
treatment to β2KO mice. *P < 0.05 versus WT. #P < 0.05 versus β2KO only. DStatistics
Statistical analyses were done using Prism software
(GraphPad, La Jolla, CA, USA). Analyses were done
using a Kruskal-Wallis test, followed by Dunn’s test.
Data are presented as mean ± SEM. For Western blots, a
representative blot is presented.
Results
Etanercept treatment restores normal insulin receptor
phosphorylation, while reducing IRS-1Ser307 levels
To insure that treatment with etanercept was able to sig-
nificantly reduce TNFα levels in β2KO mice, we per-
formed an ELISA analysis to show that β2KO mice have
increased levels of TNFα, which were significantly re-
duced by etanercept treatment (Figure 1A). Since TNFα
is a key player in insulin resistance, we wanted to inves-
tigate whether blockade of TNFα actions in β2KO mice
could prevent these deleterious effects. Etanercept treat-
ment to β2KO mice was able to significantly increase in-
sulin receptor autophosphorylation on tyrosine 1150/
1151 (Figure 1B). Since TNFα preferentially phosphory-
lates IRS-1 on serine 307 to inhibit insulin signal trans-
duction [13], we measured IRS-1Ser307 phosphorylation
after etanercept treatment. Data showed that etanercept
significantly reduced IRS-1Ser307 phosphorylation in β2KO
mice (Figure 1C), suggesting that treatment with etaner-
cept prevented TNFα-induced IRS-1 phosphorylation.
Etanercept reduced SOCS3 levels, leading to decreased
IRTyr960 phosphorylation
We have previously reported that β2KO mice have in-
creased SOCS3 levels and IRTyr960 phosphorylation [5],
which are both associated with increased TNFα levelsincreasing insulin receptor autophosphorylation. In all panels, data
O mice treated with etanercept. (A) Demonstrates that etanercept
ice. (B) Shows that insulin receptor autophosphorylation sites tyrosine
treatment. (C) Demonstrates that IRS-1Ser307 is reduced after etanercept
ata are mean ± SEM. N = 5 mice for all groups.
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that β2KO mice have increased SOCS3 (A) and IRTyr960
phosphorylation (B), as we reported previously. Add-
itionally, Figure 2 showed that inhibition of TNFα with
etanercept was able to significantly reduce both SOCS3
and IRTyr960 activity, suggesting that etanercept may pre-
vent insulin resistance in the retina.Pro-apoptotic factors are reduced after etanercept
treatment to β2KO mice
Since prevention of apoptosis is a key goal of the insu-
lin signaling pathway, we measured key pro-apoptotic
(Figure 3C-E) and anti-apoptotic markers (Figure 3A-B)
in wildtype and β2KO mice. While etanercept had no
effects on wildtype mice, etanercept treatment signifi-
cantly increased levels of key anti-apoptotic markers,
Akt (A) and Bcl-xL (B), while decreased pro-apoptotic
markers, Bax (C), Cytochrome C (D), and cleaved cas-
pase 3 (E). Taken together, the data suggest that β2KO
mice have impaired insulin signaling, which is restored
after inhibition of TNFα through etanercept therapy.Etanercept treatment improves ERG amplitudes
We have previously reported that β2KO mice have re-
duced amplitudes of the A-wave, B-wave and oscillatory
potentials [5], which was improved with treatment with
Compound 49b (Jiang et al., in press). In this study, we
found a similar reduction in ERG amplitudes in β2KO
mice compared to wildtype mice (Figure 4, red line),
which was resolved with treatment with etanercept for
two months (Figure 4, green line). Combining the cell
signaling data with functional data, this work demon-
strated that TNFα inhibition is effective in preventingFigure 2 Inhibition of TNFα with etanercept reduces suppressor of cy
shows results for wildtype (WT) and β2KO (β2KO) mice only or WT and β2KO m
demonstrating that etanercept reduced SOCS3 levels in β2KO mice. (B) Wester
that IRTyr960 is reduced after etanercept treatment. *P< 0.05 versus WT. #P< 0.0insulin resistance in the retina, leading to normal retinal
function.
Discussion
The goal of this study was to demonstrate that TNFα
plays a role in insulin resistance in β2KO mice. Since
others had reported that etanercept was effective in
eliminating diabetic-like changes in the rodent eye
[18,19], we wanted to determine if inhibition of TNFα
with etanercept in β2KO mice could restore normal in-
sulin signal transduction. We have previously demon-
strated that TNFα is key to inhibition of insulin
signaling in both retinal endothelial cells (REC) [8] and
Müller cells [20] grown in a high glucose concentration,
leading to increased apoptosis. In this data set, we dem-
onstrate that etanercept is effective at reducing TNFα-
mediated insulin resistance. Two months of etanercept
treatment, used at the same treatment regimen as that
used in humans with rheumatoid arthritis [19], led to a
significant decrease in TNFα in β2KO mice when com-
pared to untreated β2KO mice. Since we have reported
that one pathway by which TNFα can mediate insulin
resistance in REC is through phosphorylation of IRS-
1Ser307 [8], we measured this phosphorylation site in vivo
and found that etanercept reduced IRS-1Ser307 in the
β2KO mice. Another potential pathway by which TNFα
can mediate impaired insulin signaling is through activa-
tion of SOCS3 [15]. Etanercept was able to significantly
reduce SOCS3 in β2KO mice, leading to decreased
IRTyr960. Blockade of IRTyr960 phosphorylation can pro-
mote normal insulin signaling as IRTyr960 inhibits the
interaction between insulin receptor and IRS-1 [16].
In addition to blockade of TNFα-mediated impairment
of insulin signal transduction, etanercept also promotedtokine signaling 3 (SOCS3) and IRTyr960 levels. In all panels, data
ice treated with etanercept. (A) Western blot data on SOCS3 levels
n blot data on insulin receptor phosphorylation on tyrosine 960, showing
5 versus β2KO only. Data are mean ± SEM. N = 5 mice for all groups.
Figure 3 Etanercept treatment reduces pro-apoptotic markers. In all panels, data shows results for wildtype (WT) and β2KO (β2KO) mice
only or WT and β2KO mice treated with etanercept. (A) and (B) show that etanercept increases anti-apoptotic markers Akt (A) and Bcl-xL (B),
while (C-E) demonstrate the etanercept decreased pro-apoptotic markers Bax (C), Cytochrome C (D) and cleaved caspase 3 (E). *P < 0.05 versus
WT. #P < 0.05 versus β2KO only. Data are mean ± SEM. N = 5 mice for all groups.
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1151 in the β2KO mice, which are autophosphorylation
sites, leading to promotion of insulin signaling. We have
previously reported that insulin receptor phosphoryl-
ation is reduced in β2KO mice, which appeared to beFigure 4 Etanercept improved amplitudes of all electroretinogram (ER
(WT) and β2KO (β2KO) mice only or WT and β2KO mice treated with etane
amplitudes for A-wave (left), B-wave (middle) and oscillatory potentials (rig
SD for ERG. N = 5 mice for all groups.localized to the inner retina and ganglion cell layer [5].
Maintenance of normal insulin signal phosphorylation
by etanercept likely led to increased Akt activity and
decreased cleaved caspase 3 observed in the β2KO mice.
The reduced apoptosis and improvement in insulinG) waves in β2KO mice. In all panels, data shows results for wildtype
rcept. In mice treated with etanercept for two months, the ERG
ht) were significantly increased over β2KO only mice. Data are mean ±
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provement in the ERG after etanercept treatment.
We focus on our previous work in REC, as β2KO mice
treated with etanercept likely represent effects of TNFα
inhibition on REC only, as we have previously reported
that β2-adrenergic receptors are key for TNFα actions
in Müller cells [20,21]. Thus, use of the β2KO mice al-
lows us to dissect TNFα-mediated effects on insulin
signaling in REC versus Müller cells’ actions in vivo.
Data from etanercept-treated β2KO mice suggest that
maintenance of normal insulin signaling through TNFα
inhibition can reduce inner retinal apoptosis and im-
prove retinal function.
Others have reported that TNFα inhibition using eta-
nercept is effective at reducing diabetic-like changes in
the retina [18,19]. This study provided novel information
on potential reasons for the improvement in diabetic-
like changes; that is, reduced TNFα-mediated impair-
ment of insulin signaling. Data demonstrate that inhib-
ition of TNFα in β2KO mice led to improved insulin
receptor phosphorylation on tyrosine 1150/1151, as well
as increased anti-apoptotic proteins. Use of etanercept
in β2KO mice allowed us to dissect TNFα-mediated im-
pairment of insulin signal transduction in REC versus
Müller cells. Taken together, the present study provides
cellular signaling pathways associated with the beneficial
effects of etanercept on β2KO mice.
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